EP2322621A3 - Procédé d'isolation de polypeptides solubles - Google Patents

Procédé d'isolation de polypeptides solubles Download PDF

Info

Publication number
EP2322621A3
EP2322621A3 EP10190194A EP10190194A EP2322621A3 EP 2322621 A3 EP2322621 A3 EP 2322621A3 EP 10190194 A EP10190194 A EP 10190194A EP 10190194 A EP10190194 A EP 10190194A EP 2322621 A3 EP2322621 A3 EP 2322621A3
Authority
EP
European Patent Office
Prior art keywords
identified
polypeptides
phage
human
biophysical properties
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP10190194A
Other languages
German (de)
English (en)
Other versions
EP2322621A2 (fr
Inventor
Jamshid Tanha
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National Research Council of Canada
Original Assignee
National Research Council of Canada
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National Research Council of Canada filed Critical National Research Council of Canada
Publication of EP2322621A2 publication Critical patent/EP2322621A2/fr
Publication of EP2322621A3 publication Critical patent/EP2322621A3/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/005—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1271—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Micrococcaceae (F), e.g. Staphylococcus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1282—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
EP10190194A 2005-03-25 2006-03-24 Procédé d'isolation de polypeptides solubles Withdrawn EP2322621A3 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66495405P 2005-03-25 2005-03-25
EP06721715A EP1869182B1 (fr) 2005-03-25 2006-03-24 Procede d'isolation de polypeptides solubles

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
EP06721715.8 Division 2006-03-24

Publications (2)

Publication Number Publication Date
EP2322621A2 EP2322621A2 (fr) 2011-05-18
EP2322621A3 true EP2322621A3 (fr) 2012-09-12

Family

ID=37023360

Family Applications (46)

Application Number Title Priority Date Filing Date
EP10190153A Withdrawn EP2322622A3 (fr) 2005-03-25 2006-03-24 Procédé d'isolation de polypeptides solubles
EP10190210A Withdrawn EP2351842A1 (fr) 2005-03-25 2006-03-24 Procédé d'isolation de polypeptides solubles
EP10190145A Withdrawn EP2368994A3 (fr) 2005-03-25 2006-03-24 Procédé d'isolation de polypeptides solubles
EP10190249A Withdrawn EP2338998A1 (fr) 2005-03-25 2006-03-24 Procédé d'isolation de polypeptides solubles
EP10190086A Withdrawn EP2368990A1 (fr) 2005-03-25 2006-03-24 Procédé d'isolation de polypeptides solubles
EP10190248.4A Not-in-force EP2333066B1 (fr) 2005-03-25 2006-03-24 Procédé d'isolation de polypeptides solubles
EP10190222A Withdrawn EP2316948A1 (fr) 2005-03-25 2006-03-24 Procédé d'isolation de polypeptides solubles
EP10190194A Withdrawn EP2322621A3 (fr) 2005-03-25 2006-03-24 Procédé d'isolation de polypeptides solubles
EP10190187.4A Not-in-force EP2322624B1 (fr) 2005-03-25 2006-03-24 Procédé d'isolation de polypeptides solubles
EP10190215A Withdrawn EP2330195A3 (fr) 2005-03-25 2006-03-24 Procédé d'isolation de polypeptides solubles
EP10190235A Withdrawn EP2371961A1 (fr) 2005-03-25 2006-03-24 Procédé d'isolation de polypeptides solubles
EP10190236A Withdrawn EP2336327A1 (fr) 2005-03-25 2006-03-24 Procédé d'isolation de polypeptides solubles
EP10190149A Withdrawn EP2363485A1 (fr) 2005-03-25 2006-03-24 Procédé d'isolation de polypeptides solubles
EP10190082A Withdrawn EP2316946A1 (fr) 2005-03-25 2006-03-24 Procédé d'isolation de polypeptides solubles
EP10190162A Withdrawn EP2322623A3 (fr) 2005-03-25 2006-03-24 Procédé d'isolation de polypeptides solubles
EP10190240A Withdrawn EP2377936A3 (fr) 2005-03-25 2006-03-24 Procédé d'isolation de polypeptides solubles
EP10190143.7A Active EP2374886B1 (fr) 2005-03-25 2006-03-24 Procédé d'isolation de polypeptides solubles
EP10190233A Withdrawn EP2368996A3 (fr) 2005-03-25 2006-03-24 Procédé d'isolation de polypeptides solubles
EP06721715A Not-in-force EP1869182B1 (fr) 2005-03-25 2006-03-24 Procede d'isolation de polypeptides solubles
EP10190201A Withdrawn EP2374887A3 (fr) 2005-03-25 2006-03-24 Procédé d'isolation de polypeptides solubles
EP10190100A Withdrawn EP2368992A3 (fr) 2005-03-25 2006-03-24 Procédé d'isolation de polypeptides solubles
EP10190176A Withdrawn EP2351841A1 (fr) 2005-03-25 2006-03-24 Procédé d'isolation de polypeptides solubles
EP10190246A Withdrawn EP2333067A1 (fr) 2005-03-25 2006-03-24 Procédé d'isolation de polypeptides solubles
EP10190205A Withdrawn EP2338997A1 (fr) 2005-03-25 2006-03-24 Procédé d'isolation de polypeptides solubles
EP10190147A Withdrawn EP2368995A3 (fr) 2005-03-25 2006-03-24 Procédé d'isolation de polypeptides solubles
EP10190247A Withdrawn EP2330196A3 (fr) 2005-03-25 2006-03-24 Procédé d'isolation de polypeptides solubles
EP10190102A Withdrawn EP2368993A3 (fr) 2005-03-25 2006-03-24 Procédé d'isolation de polypeptides solubles
EP10190242.7A Active EP2360256B1 (fr) 2005-03-25 2006-03-24 Procédé d'isolation de polypeptides solubles
EP10190232A Withdrawn EP2316945A1 (fr) 2005-03-25 2006-03-24 Procédé d'isolation de polypeptides solubles
EP10190237A Withdrawn EP2336328A1 (fr) 2005-03-25 2006-03-24 Procédé d'isolation de polypeptides solubles
EP10190169A Withdrawn EP2336326A3 (fr) 2005-03-25 2006-03-24 Procédé d'isolation de polypeptides solubles
EP10190177A Withdrawn EP2339000A1 (fr) 2005-03-25 2006-03-24 Procédé d'isolation de polypeptides solubles
EP10190158A Withdrawn EP2339001A2 (fr) 2005-03-25 2006-03-24 Procédé d'isolation de polypeptides solubles
EP10190173A Withdrawn EP2371960A3 (fr) 2005-03-25 2006-03-24 Procédé d'isolation de polypeptides solubles
EP10190180A Withdrawn EP2345723A1 (fr) 2005-03-25 2006-03-24 Procédé d'isolation de polypeptides solubles
EP10190104A Withdrawn EP2336323A3 (fr) 2005-03-25 2006-03-24 Procédé d'isolation de polypeptides solubles
EP10190089A Withdrawn EP2333068A1 (fr) 2005-03-25 2006-03-24 Procédé d'isolation de polypeptides solubles
EP10190093.4A Not-in-force EP2368991B1 (fr) 2005-03-25 2006-03-24 Procédé d'isolation de polypeptides solubles
EP10190160A Withdrawn EP2316947A1 (fr) 2005-03-25 2006-03-24 Procédé d'isolation de polypeptides solubles
EP10190225.2A Active EP2377935B1 (fr) 2005-03-25 2006-03-24 Procédé d'isolation de polypeptides solubles
EP10190165A Withdrawn EP2336325A1 (fr) 2005-03-25 2006-03-24 Procédé d'isolation de polypeptides solubles
EP10190155.1A Not-in-force EP2360255B1 (fr) 2005-03-25 2006-03-24 Procédé d'isolation de polypeptides solubles
EP10190206A Withdrawn EP2386638A3 (fr) 2005-03-25 2006-03-24 Procédé d'isolation de polypeptides solubles
EP10190150A Withdrawn EP2336324A2 (fr) 2005-03-25 2006-03-24 Procédé d'isolation de polypeptides solubles
EP10190091A Withdrawn EP2338999A3 (fr) 2005-03-25 2006-03-24 Procédé d'isolation de polypeptides solubles
EP10190244A Withdrawn EP2368997A3 (fr) 2005-03-25 2006-03-24 Procédé d'isolation de polypeptides solubles

Family Applications Before (7)

Application Number Title Priority Date Filing Date
EP10190153A Withdrawn EP2322622A3 (fr) 2005-03-25 2006-03-24 Procédé d'isolation de polypeptides solubles
EP10190210A Withdrawn EP2351842A1 (fr) 2005-03-25 2006-03-24 Procédé d'isolation de polypeptides solubles
EP10190145A Withdrawn EP2368994A3 (fr) 2005-03-25 2006-03-24 Procédé d'isolation de polypeptides solubles
EP10190249A Withdrawn EP2338998A1 (fr) 2005-03-25 2006-03-24 Procédé d'isolation de polypeptides solubles
EP10190086A Withdrawn EP2368990A1 (fr) 2005-03-25 2006-03-24 Procédé d'isolation de polypeptides solubles
EP10190248.4A Not-in-force EP2333066B1 (fr) 2005-03-25 2006-03-24 Procédé d'isolation de polypeptides solubles
EP10190222A Withdrawn EP2316948A1 (fr) 2005-03-25 2006-03-24 Procédé d'isolation de polypeptides solubles

Family Applications After (38)

Application Number Title Priority Date Filing Date
EP10190187.4A Not-in-force EP2322624B1 (fr) 2005-03-25 2006-03-24 Procédé d'isolation de polypeptides solubles
EP10190215A Withdrawn EP2330195A3 (fr) 2005-03-25 2006-03-24 Procédé d'isolation de polypeptides solubles
EP10190235A Withdrawn EP2371961A1 (fr) 2005-03-25 2006-03-24 Procédé d'isolation de polypeptides solubles
EP10190236A Withdrawn EP2336327A1 (fr) 2005-03-25 2006-03-24 Procédé d'isolation de polypeptides solubles
EP10190149A Withdrawn EP2363485A1 (fr) 2005-03-25 2006-03-24 Procédé d'isolation de polypeptides solubles
EP10190082A Withdrawn EP2316946A1 (fr) 2005-03-25 2006-03-24 Procédé d'isolation de polypeptides solubles
EP10190162A Withdrawn EP2322623A3 (fr) 2005-03-25 2006-03-24 Procédé d'isolation de polypeptides solubles
EP10190240A Withdrawn EP2377936A3 (fr) 2005-03-25 2006-03-24 Procédé d'isolation de polypeptides solubles
EP10190143.7A Active EP2374886B1 (fr) 2005-03-25 2006-03-24 Procédé d'isolation de polypeptides solubles
EP10190233A Withdrawn EP2368996A3 (fr) 2005-03-25 2006-03-24 Procédé d'isolation de polypeptides solubles
EP06721715A Not-in-force EP1869182B1 (fr) 2005-03-25 2006-03-24 Procede d'isolation de polypeptides solubles
EP10190201A Withdrawn EP2374887A3 (fr) 2005-03-25 2006-03-24 Procédé d'isolation de polypeptides solubles
EP10190100A Withdrawn EP2368992A3 (fr) 2005-03-25 2006-03-24 Procédé d'isolation de polypeptides solubles
EP10190176A Withdrawn EP2351841A1 (fr) 2005-03-25 2006-03-24 Procédé d'isolation de polypeptides solubles
EP10190246A Withdrawn EP2333067A1 (fr) 2005-03-25 2006-03-24 Procédé d'isolation de polypeptides solubles
EP10190205A Withdrawn EP2338997A1 (fr) 2005-03-25 2006-03-24 Procédé d'isolation de polypeptides solubles
EP10190147A Withdrawn EP2368995A3 (fr) 2005-03-25 2006-03-24 Procédé d'isolation de polypeptides solubles
EP10190247A Withdrawn EP2330196A3 (fr) 2005-03-25 2006-03-24 Procédé d'isolation de polypeptides solubles
EP10190102A Withdrawn EP2368993A3 (fr) 2005-03-25 2006-03-24 Procédé d'isolation de polypeptides solubles
EP10190242.7A Active EP2360256B1 (fr) 2005-03-25 2006-03-24 Procédé d'isolation de polypeptides solubles
EP10190232A Withdrawn EP2316945A1 (fr) 2005-03-25 2006-03-24 Procédé d'isolation de polypeptides solubles
EP10190237A Withdrawn EP2336328A1 (fr) 2005-03-25 2006-03-24 Procédé d'isolation de polypeptides solubles
EP10190169A Withdrawn EP2336326A3 (fr) 2005-03-25 2006-03-24 Procédé d'isolation de polypeptides solubles
EP10190177A Withdrawn EP2339000A1 (fr) 2005-03-25 2006-03-24 Procédé d'isolation de polypeptides solubles
EP10190158A Withdrawn EP2339001A2 (fr) 2005-03-25 2006-03-24 Procédé d'isolation de polypeptides solubles
EP10190173A Withdrawn EP2371960A3 (fr) 2005-03-25 2006-03-24 Procédé d'isolation de polypeptides solubles
EP10190180A Withdrawn EP2345723A1 (fr) 2005-03-25 2006-03-24 Procédé d'isolation de polypeptides solubles
EP10190104A Withdrawn EP2336323A3 (fr) 2005-03-25 2006-03-24 Procédé d'isolation de polypeptides solubles
EP10190089A Withdrawn EP2333068A1 (fr) 2005-03-25 2006-03-24 Procédé d'isolation de polypeptides solubles
EP10190093.4A Not-in-force EP2368991B1 (fr) 2005-03-25 2006-03-24 Procédé d'isolation de polypeptides solubles
EP10190160A Withdrawn EP2316947A1 (fr) 2005-03-25 2006-03-24 Procédé d'isolation de polypeptides solubles
EP10190225.2A Active EP2377935B1 (fr) 2005-03-25 2006-03-24 Procédé d'isolation de polypeptides solubles
EP10190165A Withdrawn EP2336325A1 (fr) 2005-03-25 2006-03-24 Procédé d'isolation de polypeptides solubles
EP10190155.1A Not-in-force EP2360255B1 (fr) 2005-03-25 2006-03-24 Procédé d'isolation de polypeptides solubles
EP10190206A Withdrawn EP2386638A3 (fr) 2005-03-25 2006-03-24 Procédé d'isolation de polypeptides solubles
EP10190150A Withdrawn EP2336324A2 (fr) 2005-03-25 2006-03-24 Procédé d'isolation de polypeptides solubles
EP10190091A Withdrawn EP2338999A3 (fr) 2005-03-25 2006-03-24 Procédé d'isolation de polypeptides solubles
EP10190244A Withdrawn EP2368997A3 (fr) 2005-03-25 2006-03-24 Procédé d'isolation de polypeptides solubles

Country Status (10)

Country Link
US (5) US8293233B2 (fr)
EP (46) EP2322622A3 (fr)
JP (7) JP5171611B2 (fr)
AT (1) ATE531800T1 (fr)
AU (1) AU2006227536B9 (fr)
CA (8) CA2873906C (fr)
ES (8) ES2531537T3 (fr)
PL (1) PL2360255T3 (fr)
PT (1) PT2360255E (fr)
WO (1) WO2006099747A1 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002083855A2 (fr) 2001-04-16 2002-10-24 Wyeth Holdings Corporation Nouveaux cadres de lecture ouverts de streptococcus pneumoniae codant pour des antigenes polypeptidiques, et leurs utilisations
WO2007001423A2 (fr) 2004-10-21 2007-01-04 Wyeth Compositions immunogenes a base de polypeptides antigenes de staphylococcus epidermidis
EP2322622A3 (fr) * 2005-03-25 2012-03-07 National Research Council of Canada Procédé d'isolation de polypeptides solubles
WO2009000099A2 (fr) 2007-06-25 2008-12-31 Esbatech Ag Méthodes de modification d'anticorps et anticorps modifiés présentant des propriétés fonctionnelles améliorées
EP2238165B1 (fr) * 2008-01-07 2017-07-05 Government of the United States of America, as represented by the Secretary, Department of Health and Human Services Anticorps à domaine anti-vih et procédé de fabrication et d'utilisation de ceux-ci
WO2010060216A1 (fr) * 2008-11-26 2010-06-03 National Research Council Of Canada Billes incluses dans un nanoagrégat conjuguées à des anticorps à un seul domaine
EP2632949B1 (fr) * 2010-10-25 2017-09-13 National Research Council of Canada Anticorps spécifiques de clostridium difficile et leurs applications
ES2746559T3 (es) * 2011-01-28 2020-03-06 Nat Res Council Canada Modificación genética de dominios de inmunoglobulina
CN104781277A (zh) * 2012-09-13 2015-07-15 诺华股份有限公司 具有末端修饰的抗原结合分子
CN105531370A (zh) 2013-04-23 2016-04-27 阿伯丁大学理事会 治疗靶向特异性vnar结构域与icosl的分离
JP2018505662A (ja) * 2014-12-19 2018-03-01 メッドイミューン・リミテッド 血液脳関門輸送分子およびそれらの使用
MX2017009537A (es) 2015-01-23 2018-04-10 Helix Biopharma Corp Conjugados ureasa-anticuerpo con fines terapeuticos.
BR112018008891A8 (pt) 2015-11-03 2019-02-26 Janssen Biotech Inc anticorpos que se ligam especificamente a pd-1 e tim-3 e seus usos
US20210024586A1 (en) * 2018-03-06 2021-01-28 Precigen, Inc. Human papillomavirus vaccines and uses of the same
CA3092935A1 (fr) 2018-03-06 2019-09-12 Precigen, Inc. Vaccins contre l'hepatite b et utilisations de ces derniers
US11548938B2 (en) 2018-08-21 2023-01-10 Quidel Corporation DbpA antibodies and uses thereof
JP2023507083A (ja) 2019-12-19 2023-02-21 クイデル コーポレーション モノクローナル抗体融合物
AR124914A1 (es) * 2021-02-18 2023-05-17 Mitsubishi Tanabe Pharma Corp Nuevo anticuerpo anti-pad4

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998001581A1 (fr) * 1996-07-09 1998-01-15 Recombinant Biocatalysis, Inc. Methode de remaniement d'adn avec des polynucleotides obtenus par blocage ou interruption d'un processus de synthese ou d'amplification
WO2002051870A2 (fr) * 2000-12-22 2002-07-04 GRAD, Carole Legal Representative of KAPLAN, Howard Bibliotheques d'affichage de phages de fragments vh humains
WO2004005890A2 (fr) * 2002-07-03 2004-01-15 The Trustees Of The University Of Pennsylvania Compositions, procedes et kits ayant trait a des auto-anticorps antiplaquettaires et leurs inhibiteurs
EP1479694A2 (fr) * 1999-12-28 2004-11-24 Esbatech AG Anticorps simple chaine ScFv avec des structures définies (régions d'encadrement) stable dans un environnement réducteur

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP0542810A1 (fr) * 1990-08-02 1993-05-26 B.R. Centre Limited Procedes de production de proteines presentant une fonction souhaitee
ES2202310T3 (es) * 1991-12-13 2004-04-01 Xoma Corporation Metodos y materiales para la preparacion de dominios variables de anticuerpos modificados y sus usos terapeuticos.
US6596850B1 (en) * 1998-01-30 2003-07-22 Ixsys, Incorporated Anti-αv3β3 recombinant human antibodies, nucleic acids encoding same
US5994511A (en) 1997-07-02 1999-11-30 Genentech, Inc. Anti-IgE antibodies and methods of improving polypeptides
WO2000061635A2 (fr) * 1999-04-09 2000-10-19 Universität Zürich Procede de stabilisation d'immunoglobulines chimeres ou de fragments d'immunoglobuline chimere, et fragment de scfv anti-egp-2 stabilise
GB9911569D0 (en) * 1999-05-18 1999-07-21 Oxford Biomedica Ltd Antibodies
EP1268555A2 (fr) * 2000-03-27 2003-01-02 The Regents of The University of California Ligands diriges contre le composant non secreteur et la region du filament d'un pigr et procedes d'utilisation associes
CA2402780A1 (fr) 2000-03-29 2001-10-04 Dgi Biotechnologies, L.L.C. Agonistes et antagonistes du recepteur de l'insuline et d'igf-1
ATE365749T1 (de) 2000-05-12 2007-07-15 Gpc Biotech Ag Humane peptide/proteine, die das töten von zellen,einschliesslich lymphoide tumorzellen, herbeiführen oder bewirken
NZ522700A (en) * 2000-06-16 2006-02-24 Human Genome Sciences Inc Antibodies that immunospecifically bind to blys
JP3375941B2 (ja) * 2000-11-24 2003-02-10 科学技術振興事業団 高効率抗体スクリーニング法
WO2002059340A1 (fr) * 2001-01-26 2002-08-01 The Scripps Research Institute Immunopolypeptides diriges contre le virus de l'hepatite c
DE10123041A1 (de) * 2001-05-11 2002-11-28 Tobias Heintges Humane hochaffine Antikörperfragmente gegen essentielle Proteine von Hepatitis-C-Virus
WO2004003019A2 (fr) * 2002-06-28 2004-01-08 Domantis Limited Ligand
EP1425694A2 (fr) 2001-08-03 2004-06-09 Medical Research Council Methode pour identifier la sequence consensus pour des anticorps intracellulaires
EP1429143A4 (fr) * 2001-08-22 2006-04-12 Inst Antibodies Co Ltd Procede de selection d'une molecule de liaison
GB0124317D0 (en) * 2001-10-10 2001-11-28 Celltech R&D Ltd Biological products
JP2005533486A (ja) * 2002-02-20 2005-11-10 ダイアックス、コープ Ｍｈｃ−ペプチド複合体結合リガンド
GB0226727D0 (en) 2002-11-15 2002-12-24 Medical Res Council Intrabodies
HUE048922T2 (hu) 2002-05-22 2020-09-28 Novartis Ag Immunglobulin vázrégiók, amelyek intracelluláris környezetben fokozott stabilitást mutatnak, továbbá eljárások azonosításukra
WO2003102136A2 (fr) * 2002-05-30 2003-12-11 Human Genome Sciences, Inc. Anticorps se fixant specifiquement a la neurokinine b
AU2003239197A1 (en) 2002-06-07 2003-12-22 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Novel stable anti-cd22 antibodies
CA2506128A1 (fr) 2002-11-15 2004-06-03 Medical Research Council Anticorps anti-ras activee
RU2005131852A (ru) * 2003-03-14 2006-04-20 Уайт (Us) Антитела против человеческого рецептора il-21 и их применение
EP1633316A4 (fr) 2003-05-06 2008-04-02 Human Genome Sciences Inc Anticorps se liant de maniere immunospecifique aux recepteurs trail
AR045614A1 (es) 2003-09-10 2005-11-02 Hoffmann La Roche Anticuerpos contra el recepctor de la interleuquina- 1 y los usos de los mismos
TWI333977B (en) 2003-09-18 2010-12-01 Symphogen As Method for linking sequences of interest
JP2007530045A (ja) 2004-03-23 2007-11-01 アムジエン・インコーポレーテツド ヒトｏｘ４０ｌ（ｃｄ１３４ｌ）特異性モノクローナル抗体
AU2005267720B2 (en) * 2004-08-05 2012-02-23 Genentech, Inc. Humanized anti-cmet antagonists
EP1789451A4 (fr) * 2004-08-12 2009-12-02 Dyax Corp Protéines de liaison au complexe tie
EP2322622A3 (fr) 2005-03-25 2012-03-07 National Research Council of Canada Procédé d'isolation de polypeptides solubles
WO2010060216A1 (fr) * 2008-11-26 2010-06-03 National Research Council Of Canada Billes incluses dans un nanoagrégat conjuguées à des anticorps à un seul domaine
ES2746559T3 (es) * 2011-01-28 2020-03-06 Nat Res Council Canada Modificación genética de dominios de inmunoglobulina
CN104781277A (zh) * 2012-09-13 2015-07-15 诺华股份有限公司 具有末端修饰的抗原结合分子

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998001581A1 (fr) * 1996-07-09 1998-01-15 Recombinant Biocatalysis, Inc. Methode de remaniement d'adn avec des polynucleotides obtenus par blocage ou interruption d'un processus de synthese ou d'amplification
EP1479694A2 (fr) * 1999-12-28 2004-11-24 Esbatech AG Anticorps simple chaine ScFv avec des structures définies (régions d'encadrement) stable dans un environnement réducteur
WO2002051870A2 (fr) * 2000-12-22 2002-07-04 GRAD, Carole Legal Representative of KAPLAN, Howard Bibliotheques d'affichage de phages de fragments vh humains
WO2004005890A2 (fr) * 2002-07-03 2004-01-15 The Trustees Of The University Of Pennsylvania Compositions, procedes et kits ayant trait a des auto-anticorps antiplaquettaires et leurs inhibiteurs

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
HUDSON P J ET AL: "High avidity scFv multimers; diabodies and triabodies", JOURNAL OF IMMUNOLOGICAL METHODS, ELSEVIER SCIENCE PUBLISHERS B.V.,AMSTERDAM, NL, vol. 231, no. 1-2, 10 December 1999 (1999-12-10), pages 177 - 189, XP004186084, ISSN: 0022-1759, DOI: 10.1016/S0022-1759(99)00157-X *
TO R ET AL: "Isolation of Monomeric Human VHS by a Phage Selection", JOURNAL OF BIOLOGICAL CHEMISTRY, THE AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, INC, US, vol. 280, no. 50, 16 December 2005 (2005-12-16), pages 41395 - 41403, XP009100333, ISSN: 0021-9258, DOI: 10.1074/JBC.M509900200 *
WANG XIANG-BIN ET AL: "A new approach for rapidly reshaping single-chain antibody in vitro by combining DNA shuffling with ribosome display", JOURNAL OF BIOCHEMISTRY (TOKYO), vol. 136, no. 1, July 2004 (2004-07-01), pages 19 - 28, XP002626886, ISSN: 0021-924X *
WOERN A ET AL: "Stability engineering of antibody single-chain Fv fragments", JOURNAL OF MOLECULAR BIOLOGY, LONDON, GB, vol. 305, no. 5, 1 January 2001 (2001-01-01), pages 989 - 1010, XP002249286, ISSN: 0022-2836, DOI: 10.1006/JMBI.2000.4265 *

Also Published As

Publication number Publication date
PT2360255E (pt) 2015-04-08
JP2019187439A (ja) 2019-10-31
EP2368996A3 (fr) 2011-12-14
EP2368992A3 (fr) 2012-03-14
JP2016073284A (ja) 2016-05-12
EP2338999A2 (fr) 2011-06-29
EP2371961A1 (fr) 2011-10-05
EP2377936A3 (fr) 2012-06-13
EP2368990A1 (fr) 2011-09-28
EP1869182A1 (fr) 2007-12-26
EP2333068A1 (fr) 2011-06-15
CA2868865A1 (fr) 2006-09-28
ATE531800T1 (de) 2011-11-15
EP2316945A1 (fr) 2011-05-04
JP2018110583A (ja) 2018-07-19
EP2351841A1 (fr) 2011-08-03
US20190092840A1 (en) 2019-03-28
EP2345723A1 (fr) 2011-07-20
EP2316947A1 (fr) 2011-05-04
EP2368991B1 (fr) 2016-02-17
JP6628822B2 (ja) 2020-01-15
EP2363485A1 (fr) 2011-09-07
US8293233B2 (en) 2012-10-23
WO2006099747A1 (fr) 2006-09-28
ES2534305T3 (es) 2015-04-21
EP2360255A1 (fr) 2011-08-24
EP2374886B1 (fr) 2015-11-11
JP2012070748A (ja) 2012-04-12
AU2006227536B9 (en) 2011-08-18
CA2868774A1 (fr) 2006-09-28
CA2873906C (fr) 2020-11-24
EP2336324A2 (fr) 2011-06-22
US20220017603A1 (en) 2022-01-20
EP2322621A2 (fr) 2011-05-18
EP2377935A1 (fr) 2011-10-19
EP2336328A1 (fr) 2011-06-22
ES2536995T3 (es) 2015-06-01
EP2330195A3 (fr) 2012-05-23
EP2360256B1 (fr) 2014-12-31
CA2602028A1 (fr) 2006-09-28
CA2873906A1 (fr) 2006-09-28
JP2016103998A (ja) 2016-06-09
EP2336323A3 (fr) 2012-05-23
EP2368994A2 (fr) 2011-09-28
EP2368996A2 (fr) 2011-09-28
CA2873939C (fr) 2020-11-10
EP2374886A3 (fr) 2011-11-23
EP2333066B1 (fr) 2015-02-18
EP2322622A2 (fr) 2011-05-18
JP6878508B2 (ja) 2021-05-26
EP2371960A3 (fr) 2012-01-11
EP2368992A2 (fr) 2011-09-28
EP2368994A3 (fr) 2012-04-18
ES2558338T3 (es) 2016-02-03
EP2330195A2 (fr) 2011-06-08
EP2338998A1 (fr) 2011-06-29
PL2360255T3 (pl) 2015-05-29
JP2014144010A (ja) 2014-08-14
EP2368993A3 (fr) 2012-06-13
EP2368997A3 (fr) 2012-02-22
EP2360256A1 (fr) 2011-08-24
EP2368993A2 (fr) 2011-09-28
JP5171611B2 (ja) 2013-03-27
EP2360255B1 (fr) 2015-01-28
EP2339001A2 (fr) 2011-06-29
CA2868781A1 (fr) 2006-09-28
US10150807B2 (en) 2018-12-11
EP2338999A3 (fr) 2012-05-23
ES2375826T3 (es) 2012-03-06
EP2386638A2 (fr) 2011-11-16
US20090220485A1 (en) 2009-09-03
US20160052995A1 (en) 2016-02-25
EP2377936A2 (fr) 2011-10-19
US20130142780A1 (en) 2013-06-06
EP2316948A1 (fr) 2011-05-04
EP2368991A3 (fr) 2012-07-25
EP2336327A1 (fr) 2011-06-22
EP2330196A2 (fr) 2011-06-08
CA2868867A1 (fr) 2006-09-28
EP2368991A2 (fr) 2011-09-28
EP2386638A3 (fr) 2012-08-15
EP2368995A2 (fr) 2011-09-28
CA2873899A1 (fr) 2006-09-28
EP2322622A3 (fr) 2012-03-07
EP2322623A2 (fr) 2011-05-18
EP2368995A3 (fr) 2012-01-18
EP2330196A3 (fr) 2012-04-18
EP1869182B1 (fr) 2011-11-02
EP2322623A3 (fr) 2011-10-19
ES2546788T3 (es) 2015-09-28
EP2336323A2 (fr) 2011-06-22
EP2336325A1 (fr) 2011-06-22
EP2377935B1 (fr) 2015-07-15
EP2339000A1 (fr) 2011-06-29
EP2338997A1 (fr) 2011-06-29
EP2322624A2 (fr) 2011-05-18
CA2602028C (fr) 2015-01-13
EP2333066A1 (fr) 2011-06-15
EP2336326A2 (fr) 2011-06-22
EP2316946A1 (fr) 2011-05-04
ES2550836T3 (es) 2015-11-12
EP2374887A2 (fr) 2011-10-12
JP2008536490A (ja) 2008-09-11
JP6374851B2 (ja) 2018-08-15
ES2531537T3 (es) 2015-03-17
ES2565782T3 (es) 2016-04-06
EP2374886A2 (fr) 2011-10-12
EP2351842A1 (fr) 2011-08-03
US11091536B2 (en) 2021-08-17
EP1869182A4 (fr) 2008-08-13
CA2873939A1 (fr) 2006-09-28
EP2333067A1 (fr) 2011-06-15
AU2006227536A1 (en) 2006-09-28
EP2322624B1 (fr) 2015-09-23
CA2873899C (fr) 2020-11-10
AU2006227536B2 (en) 2011-08-11
JP5901679B2 (ja) 2016-04-13
EP2371960A2 (fr) 2011-10-05
EP2322624A3 (fr) 2012-03-14
EP2374887A3 (fr) 2012-07-18
EP2336326A3 (fr) 2012-02-15
EP2368997A2 (fr) 2011-09-28
JP5731956B2 (ja) 2015-06-10

Similar Documents

Publication Publication Date Title
EP2386638A3 (fr) Procédé d'isolation de polypeptides solubles
EP2361926A3 (fr) Polypeptides de yersinia spp. et leurs procedes d'utilisation
EP2606933A3 (fr) Combinaison de d'un inhibiteur de IAP et d'un taxane
WO2007084264A3 (fr) Procedes d’imagerie myocardique
EP2062917A3 (fr) Anticorps du récepteurs de l'érythropoïétine et leurs utilisations
EP2363460A3 (fr) Protéases fongiques acides
EP2386539A3 (fr) Composés modifiés de mimétiques de la lysine
EP3196213A3 (fr) Anticorps dirigés contre her-3 et leurs utilisations
WO2004093645A3 (fr) Mutants de transposase tn5 et leur utilisation
EP2402321A3 (fr) Dérivés chimiques de jasmonate, compositions pharmaceutiques et leurs procédés d'utilisation
EP2789626A3 (fr) Peptides et compositions destinés à prévenir l'adhérence cellulaire et procédés d'utilisation de ceux-ci
DE502005000428D1 (de) Verfahren zur Herstellung von 1,2-Diaminocyclohexan-Platin(II)-Komplexen
EP2322209A3 (fr) Épitopes d'oligosaccharides spécifiques des tumeurs et leur utilisation.
WO2007060671A3 (fr) Nouvelles sequences de nucleotides et d'acides amines, ainsi que tests et procedes d'utilisation de ces sequences a des fins de diagnostic
WO2007044844A3 (fr) Marquage de cadavres et prelevement d'adn sur des cadavres
WO2003044047A3 (fr) Genes de virulence, proteines, et leurs utilisations
WO2005023979A3 (fr) Molecules d'acide nucleique de s. mansoni isolees et utilisations associees
EP3219720A3 (fr) Peptides à épitope wdrpuh et vaccins les contenant
WO2007068913A3 (fr) Protéines contenant le domaine SRCR-B
WO2007108903A3 (fr) Vaccins contre campylobacter et procedes d'utilisation
WO2004101618A3 (fr) Proteines associees au recepteur de progestine yol002c-cgi-45
WO2007020405A3 (fr) Nouveaux peptides et utilisations associees
WO2004108079A3 (fr) Proteines interagissant avec la parkine
Luczynski Aminoestry kwasow tluszczowych jako substancje lizosomotropowe.
WO2006008266A3 (fr) Proteines de liaison au facteur xi

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AC Divisional application: reference to earlier application

Ref document number: 1869182

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 16/12 20060101ALI20120807BHEP

Ipc: C07K 16/00 20060101AFI20120807BHEP

Ipc: G01N 33/68 20060101ALI20120807BHEP

Ipc: C12N 15/10 20060101ALI20120807BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20130313